Internal Reference Number: FOI_8323
Date Request Received: 02/12/2024 00:00:00
Date Request Replied To: 30/12/2024 00:00:00
This response was sent via: By Email
Request Summary: lung cancer
Request Category: Private Individuals
| Question Number 1: I hope you鈥檒l be able to help me with an FOI request about lung cancer Question One: How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� Atezolizumab (Tecentriq) 鈥� Durvalumab (Imfinzi) 鈥� Nivolumab (Opdivo) 鈥� Pembrolizumab (Keytruda) 鈥� Chemotherapy 鈥� Radiotherapy 鈥� Chemotherapy AND Radiotherapy | |
| Answer To Question 1: 鈥� Atezolizumab (Tecentriq) <5 鈥� Durvalumab (Imfinzi) 0 鈥� Nivolumab (Opdivo) 0 鈥� Pembrolizumab (Keytruda) <5 鈥� Chemotherapy 7 鈥� Radiotherapy - unable to answer as Radiotherapy is not provided at SFT. 鈥� Chemotherapy AND Radiotherapy - unable to answer as Radiotherapy is not provided at SFT. | |
| Question Number 2: Question Two: How many patients has your Trust treated in total in the past 3 months for 鈥� Stage 2 Non Small Cell Lung Cancer 鈥� Stage 3 Non Small Cell Lung Cancer | |
| Answer To Question 2: Stage 2 Non Small Cell Lung Cancer- zero Stage 3 Non Small Cell Lung Cancer- <5 | |
| Question Number 3: Question Three: How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received: Pembrolizumab Monotherapy 1. Treatment every 3 weeks (200mg, Q3W) 2. Treatment every 6 weeks (400mg, Q6W) Pembrolizumab in combination with chemotherapy 1. Treatment every 3 weeks (200mg, Q3W) 2. Treatment every 6 weeks (400mg, Q6W) | |
| Answer To Question 3: 1 treatment 3 weekly as monotherapy 4 patients Combination treatment point 1 there were 4 patients. The responses to the other parts of question 3 were zero. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
